drugset
drugset / Trial / NCT07492316

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

NCT07492316 ↗

Phase 1 Recruiting 24 enrolled University of Florida Pediatric Neuro-Oncology Consortium · collab
NaSingle-groupOpen-labelTreatment

Summary

The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)

Timeline

Start
2026-04-24
Primary completion
2030-09-01
Completion
2031-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject RNA-LPs Vaccine — Intravenous

Indications

medulloblastoma